Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with $1.2 billion under management.
We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises of about 100 companies that develop breakthrough solutions to substantial unmet needs.
THE LEGACY OF
Pontifax began with the vision of our co-founder and chairman Eli Hurvitz (1932-2011), the legendary CEO and chairman of Teva Pharmaceuticals who spearheaded its strategy to become one of the world’s largest pharmaceutical companies. Under Eli’s guidance, we accumulated the experience and acquired the know-how required to foster life sciences innovations from inception to full-fledged, viable, operating companies. Eli’s legacy continues to guide our choices and decisions today.
INVESTING IN BREAKTHROUGH
Pontifax invests in breakthrough innovation regardless of therapeutic area or development stage. We establish our own companies as well as partner with existing management to nurture start-ups to maturity. Pontifax takes a hands-on approach in its portfolio management and is deeply involved in charting the course of each company.